Fibrosis, which is characterized by excessive deposition of extracellular matrix, is a common feature of chronic tissue injuries. Liver fibrosis leads to severe pathophysiological disturbance in the liver regardless of its etiology. Advanced fibrotic changes have been considered irreversible even after withdrawal of the liver-injuring agent. Fibrosis, however, is now regarded as a dynamic and potentially reversible process. In addition to the liver, recent studies have revealed that fibrosis plays a pivotal role in the pathogenesis of pancreatic diseases, such as chronic pancreatitis and pancreas cancer. Although enormous efforts are being made to develop anti-fibrotic therapies, no modalities have been approved for humans yet against liver and pancreatic fibrosis. The aim of this session is to provide information regarding the recent progress related to hepatic and pancreatic fibrosis from basic and clinical results. We would also like to discuss how to overcome various problems for future clinical implications. We encourage all of you to contribute to this important symposium both from the perspective of basic science and from the perspective of clinical practice.